Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 1
Expert Insights on Recent Advancements in LS-SCLC
Panelists discuss how the ADRIATIC regimen integrates immunotherapy post-chemoradiation in late-stage small cell lung cancer (LS-SCLC). In patients with paraneoplastic syndromes or immune disorders, immunotherapy requires caution. Prophylactic cranial irradiation (PCI) is considered for high-risk cases, while MRI surveillance is preferred for select patients to reduce neurotoxicity.
Video Player is loading.
Video content above is prompted by the following:
- How are you incorporating the ADRIATIC regimen into your clinical practice?
- What is the role of immunotherapy in patients with LS-SCLC and paraneoplastic syndromes or immune disorders, and how might you approach treatment in this patient subgroup?
- What is the role of prophylactic cranial radiation in LS-SCLC? In which patients would you consider PCI vs MRI surveillance alone?